Search Results - "Flechais, Aulde"

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up by Jackisch, Christian, Hegg, Roberto, Stroyakovskiy, Daniil, Ahn, Jin-Seok, Melichar, Bohuslav, Chen, Shin-Cheh, Kim, Sung-Bae, Lichinitser, Mikhail, Starosławska, Elżbieta, Kunz, Georg, Falcon, Silvia, Chen, Shou-Tung, Crepelle-Fléchais, Aulde, Heinzmann, Dominik, Shing, Mona, Pivot, Xavier

“…Abstract Background In the phase III, open-label, randomised HannaH study, fixed-dose neoadjuvant–adjuvant subcutaneous trastuzumab for human epidermal growth…”
Get full text

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results by Lindeman, Geoffrey J, Fernando, Tharu M, Bowen, Rebecca, Jerzak, Katarzyna J, Song, Xinni, Decker, Thomas, Boyle, Frances, McCune, Steve, Armstrong, Anne, Shannon, Catherine, Bertelli, Gianfilippo, Chang, Ching-Wei, Desai, Rupal, Gupta, Kushagra, Wilson, Timothy R, Flechais, Aulde, Bardia, Aditya

“…Despite promising activity in hematopoietic malignancies, efficacy of the B-cell lymphoma 2 (BCL2) inhibitor venetoclax in solid tumors is unknown. We report…”
Get full text

INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA -mutated (mut) locally advanced or metastatic breast cancer (LA/mBC) by Juric, Dejan, Kalinsky, Kevin, Im, Seock-Ah, Ciruelos, Eva M, Bianchini, Giampaolo, Barrios, Carlos H., Jacot, William, Schmid, Peter, Loi, Sherene, Rugo, Hope S., Craine, Veronica, Hutchinson, Katherine E., Flechais, Aulde, Thanopoulou, Eirini, Harbeck, Nadia

“…TPS1123 Background: Standard-of-care (SoC) endocrine therapy (ET) for pts with HR+, HER2– LA/mBC was transformed by combinations with cyclin-dependent kinase…”
Get full text

Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA by Lindeman, Geoffrey J, Bardia, Aditya, Bowen, Rebecca, Flechais, Aulde, Lei, Guiyuan, Hogea, Alexandra, Mobasher, Mehrdad, Rafii, Saeed

“…Abstract only TPS1108 Background: CDK4/6 inhibitors (CDK4/6is) administered with endocrine therapy have demonstrated improvements in progression-free survival…”
Get full text

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC) by Lindeman, Geoffrey J, Bowen, Rebecca, Jerzak, Katarzyna Joanna, Song, Xinni, Decker, Thomas, Boyle, Frances M., McCune, Steven L., Armstrong, Anne, Shannon, Catherine M., Bertelli, Gianfilippo, Fernando, Tharu M, Desai, Rupal, Gupta, Kushagra, Hsu, Jerry Y., Flechais, Aulde, Bardia, Aditya

“…Abstract only 1004 Background: For patients (pts) with ER-positive, HER2-negative MBC, CDK4/6 inhibitors + endocrine therapy (ET) is standard first-line…”
Get full text

Abstract PO2-19-08: INAVO121: Phase III study of inavolisib + fulvestrant vs alpelisib + fulvestrant in patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer by Juric, Dejan, Kalinsky, Kevin, Im, Seock-Ah, Ciruelos, Eva, Bianchini, Giampaolo, Barrios, Carlos, Jacot, William, Schmid, Peter, Loi, Sherene, Rugo, Hope, Craine, Veronica, Hutchinson, Katherine, Flechais, Aulde, Thanopoulou, Eirini, Harbeck, Nadia

“…Abstract BACKGROUND Standard-of-care (SoC) endocrine therapy (ET) for patients (pts) with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally…”
Get full text

Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC) by Jackisch, Christian, Hegg, Roberto, Stroyakovskiy, Daniil, Ahn, Jin Seok, Melichar, Bohuslav, Chen, Shin-Cheh, Crepelle-Flechais, Aulde, Heinzmann, Dominik, Shing, Mona, Pivot, Xavier B.

“…Abstract only…”
Get full text

Abstract P5-13-06: Exploratory biomarker analysis in VERONICA, a phase 2 study of venetoclax + fulvestrant versus fulvestrant in patients with estrogen receptor (ER)-positive HER2-negative metastatic breast cancer (mBC) by Lindeman, Geoffrey J., Fernando, Tharu M., Bowen, Rebecca, Chang, Ching-Wei, Desai, Rupal, Gupta, Kushagra, Fléchais, Aulde, Wilson, Timothy R., Bardia, Aditya

“…Abstract BACKGROUND: Venetoclax (VEN) is a potent and selective inhibitor of the anti-apoptotic protein, BCL2. Preclinical studies have implicated the BCL2…”
Get full text